Tags

Type your tag names separated by a space and hit enter

Decursin and decursinol angelate inhibit VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling pathway.
Carcinogenesis. 2009 Apr; 30(4):655-61.C

Abstract

Inhibition of angiogenesis is an attractive approach for the treatment of angiogenic diseases, such as cancer. Vascular endothelial growth factor (VEGF) is one of the most important activators of angiogenesis and interacts with the high-affinity tyrosine kinase receptors, VEGFR-1 and VEGFR-2. The pyranocoumarin compounds decursin and decursinol angelate isolated from the herb, Angelica gigas, are known to possess potent anti-inflammatory activities. However, little is known about their antiangiogenic activity or their underlying mechanisms. Here, we show the antiangiogenic effects of decursin and decursinol angelate using in vitro assays and in vivo animal experiments. Decursin and decursinol angelate inhibited VEGF-induced angiogenic processes in vitro, including proliferation, migration and tube formation of human umbilical vein endothelial cells. Decursin and decursinol angelate significantly suppressed neovessel formation in chick chorioallantoic membrane and tumor growth in a mouse model. The microvessel density in tumors treated with decursin for 14 days was significantly decreased compared with a vehicle control group. Decursin and decursinol angelate inhibited VEGF-induced phosphorylation of VEGFR-2, extracellular signal-regulated kinases and c-Jun N-terminal kinase mitogen-activated protein kinases. Taken together, these results demonstrate that decursin and decursinol angelate are novel candidates for inhibition of VEGF-induced angiogenesis.

Authors+Show Affiliations

Department of Natural Sciences, School of Life Sciences and Biotechnology, Kyungpook National University, Daegu 702-701, Republic of Korea.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19228635

Citation

Jung, Myung Hwan, et al. "Decursin and Decursinol Angelate Inhibit VEGF-induced Angiogenesis Via Suppression of the VEGFR-2-signaling Pathway." Carcinogenesis, vol. 30, no. 4, 2009, pp. 655-61.
Jung MH, Lee SH, Ahn EM, et al. Decursin and decursinol angelate inhibit VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling pathway. Carcinogenesis. 2009;30(4):655-61.
Jung, M. H., Lee, S. H., Ahn, E. M., & Lee, Y. M. (2009). Decursin and decursinol angelate inhibit VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling pathway. Carcinogenesis, 30(4), 655-61. https://doi.org/10.1093/carcin/bgp039
Jung MH, et al. Decursin and Decursinol Angelate Inhibit VEGF-induced Angiogenesis Via Suppression of the VEGFR-2-signaling Pathway. Carcinogenesis. 2009;30(4):655-61. PubMed PMID: 19228635.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Decursin and decursinol angelate inhibit VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling pathway. AU - Jung,Myung Hwan, AU - Lee,Sun Hee, AU - Ahn,Eun-Mi, AU - Lee,You Mie, Y1 - 2009/02/18/ PY - 2009/2/21/entrez PY - 2009/2/21/pubmed PY - 2009/4/29/medline SP - 655 EP - 61 JF - Carcinogenesis JO - Carcinogenesis VL - 30 IS - 4 N2 - Inhibition of angiogenesis is an attractive approach for the treatment of angiogenic diseases, such as cancer. Vascular endothelial growth factor (VEGF) is one of the most important activators of angiogenesis and interacts with the high-affinity tyrosine kinase receptors, VEGFR-1 and VEGFR-2. The pyranocoumarin compounds decursin and decursinol angelate isolated from the herb, Angelica gigas, are known to possess potent anti-inflammatory activities. However, little is known about their antiangiogenic activity or their underlying mechanisms. Here, we show the antiangiogenic effects of decursin and decursinol angelate using in vitro assays and in vivo animal experiments. Decursin and decursinol angelate inhibited VEGF-induced angiogenic processes in vitro, including proliferation, migration and tube formation of human umbilical vein endothelial cells. Decursin and decursinol angelate significantly suppressed neovessel formation in chick chorioallantoic membrane and tumor growth in a mouse model. The microvessel density in tumors treated with decursin for 14 days was significantly decreased compared with a vehicle control group. Decursin and decursinol angelate inhibited VEGF-induced phosphorylation of VEGFR-2, extracellular signal-regulated kinases and c-Jun N-terminal kinase mitogen-activated protein kinases. Taken together, these results demonstrate that decursin and decursinol angelate are novel candidates for inhibition of VEGF-induced angiogenesis. SN - 1460-2180 UR - https://www.unboundmedicine.com/medline/citation/19228635/Decursin_and_decursinol_angelate_inhibit_VEGF_induced_angiogenesis_via_suppression_of_the_VEGFR_2_signaling_pathway_ L2 - https://academic.oup.com/carcin/article-lookup/doi/10.1093/carcin/bgp039 DB - PRIME DP - Unbound Medicine ER -